Compounds > pyrazines
Page last updated: 2024-08-21

pyrazines and nutlin-3a

pyrazines has been researched along with nutlin-3a in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davies-Hill, T; Jin, L; Miida, T; Miyake, K; Pittaluga, S; Raffeld, M; Rudelius, M; Sebasigari, D; Tabe, Y1
Anderson, KC; Buon, L; Charalambous, E; Chauhan, D; Clynes, M; Daskalaki, E; Hayden, PJ; Hideshima, T; Kotoula, V; McMillin, DW; Mitsiades, CS; Mitsiades, N; Munshi, NC; O'Gorman, P; Ooi, MG; Raje, NS; Richardson, PG1
Jin, L; Kojima, K; Konopleva, M; Miida, T; Pittaluga, S; Raffeld, M; Tabe, Y; Zhou, Y1
Abujamra, AL; Alemar, B; Ashton-Prolla, P; de Farias, CB; Giacomazzi, J; Hainaut, P; Hautefeuille, A; Izetti, P; Lenz, G; Osvaldt, AB; Roesler, R; Schwartsmann, G1
Davaadelger, B; Duan, L; Gitelis, S; Maki, CG; Perez, RE; Zhou, Y1
Gu, W; Sun, H; Tavana, O1

Other Studies

6 other study(ies) available for pyrazines and nutlin-3a

ArticleYear
MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Feb-01, Volume: 15, Issue:3

    Topics: AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Humans; Imidazoles; Lymphoma, Mantle-Cell; Membrane Proteins; Nuclear Proteins; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; PTEN Phosphohydrolase; Pyrazines; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Protein p53; Tumor Suppressor Proteins

2009
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Dec-01, Volume: 15, Issue:23

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Survival; Humans; Imidazoles; Multiple Myeloma; Mutation, Missense; Neoplasms, Glandular and Epithelial; Piperazines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-mdm2; Pyrazines; Tumor Suppressor Protein p53

2009
MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma.
    Cancer letters, 2010, Dec-28, Volume: 299, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imidazoles; Lymphoma, Mantle-Cell; Mitochondria; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Piperazines; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p53

2010
PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
    Investigational new drugs, 2014, Volume: 32, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Aza Compounds; Boronic Acids; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Imidazoles; Mutation; Pancreatic Neoplasms; Piperazines; Pyrazines; Quinazolines; RNA, Small Interfering; Tumor Suppressor Protein p53

2014
The IGF-1R/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis.
    Cancer biology & therapy, 2017, Nov-02, Volume: 18, Issue:11

    Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Osteosarcoma; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Receptor, IGF Type 1; Receptors, Somatomedin

2017
Targeting HAUSP in both p53 wildtype and p53-mutant tumors.
    Cell cycle (Georgetown, Tex.), 2018, Volume: 17, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Imidazoles; Indenes; Molecular Targeted Therapy; N-Myc Proto-Oncogene Protein; Neurons; Piperazines; Protease Inhibitors; Protein Stability; Proto-Oncogene Proteins c-mdm2; Pyrazines; RNA, Small Interfering; Signal Transduction; Thiophenes; Tumor Suppressor Protein p53; Ubiquitin-Specific Peptidase 7

2018